<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04023331</url>
  </required_header>
  <id_info>
    <org_study_id>CL04</org_study_id>
    <nct_id>NCT04023331</nct_id>
  </id_info>
  <brief_title>67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma</brief_title>
  <official_title>67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clarity Pharmaceuticals Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clarity Pharmaceuticals Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric&#xD;
      patients with high-risk neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to be conducted in 2 phases, a dose escalation phase and a cohort expansion&#xD;
      phase. Dose escalation will be completed using a modified 3+3 study design with up to 4&#xD;
      Cohorts of increasing doses in MBq/kg. Pre-defined Dose Limiting Toxicities will be monitored&#xD;
      for 6 weeks post administration of 67Cu-SARTATE. Once either the MTD for a single&#xD;
      administration of 67Cu-SARTATE is established, or Cohort 4 has been completed, the study will&#xD;
      be expanded to enroll an additional 10 subjects who will receive 2 therapy cycles of&#xD;
      67Cu-SARTATE at the MTD dose level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of 67Cu-SARTATE</measure>
    <time_frame>6 weeks</time_frame>
    <description>MDT as determined by cohort observations of DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of Cu-67 SARTATE using CTCAE version 4.03</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Safety will be assessed via vital signs, pathology tests (hematology, biochemistry, urinalysis, coagulation), physical examinations, ECGs and spontaneous AE reporting.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of Cu-64 SARTATE using CTCAE version 4.03</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Safety will be assessed via vital signs, pathology tests (hematology, biochemistry, urinalysis, coagulation), physical examinations, ECGs and spontaneous AE reporting.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response and best response</measure>
    <time_frame>6 to 8 weeks post final therapy</time_frame>
    <description>For patients receiving at least 1 administration of 67Cu-SARTATE, as assessed by INRC.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Neuroblastoma</condition>
  <condition>Relapsed Neuroblastoma</condition>
  <condition>Refractory Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>67Cu-SARTATE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>64Cu-SARTATE - patients will receive a bolus injection of 64Cu-SARTATE during screening, and following each 67Cu-SARTATE Therapy Cycle at a rate of 2.0 MBq/kg.&#xD;
67Cu-SARTATE - In the dose escalation phase, patients will receive a single administration of 67Cu-SARTATE as a slow IV infusion (dose will be determined based on cohort allocation). In the expansion phase, patients will receive 2 administrations of 67Cu-SARTATE a the MTD level as a slow IV infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>67Cu-SARTATE</intervention_name>
    <description>67Cu-labelled MeCOSar-Tyr3-octreotate</description>
    <arm_group_label>67Cu-SARTATE</arm_group_label>
    <other_name>Cu-67 SARTATE, copper 67 SARTATE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>64Cu-SARTATE</intervention_name>
    <description>64Cu-labelled MeCOSar-Tyr3-octreotate</description>
    <arm_group_label>67Cu-SARTATE</arm_group_label>
    <other_name>Cu-64 SARTATE, copper 64 SARTATE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant is able and willing to provide informed consent (≥18 years), or informed&#xD;
             consent is obtained by the parent or legal guardian for minor participants, with the&#xD;
             minor providing age appropriate assent, according to local law and regulations;&#xD;
&#xD;
          2. Life expectancy ≥ 12 weeks;&#xD;
&#xD;
          3. Known high-risk neuroblastoma with failure to respond to standard therapy (combination&#xD;
             chemotherapy with or without radiation and surgery), or development of PD at any time;&#xD;
&#xD;
          4. Adequate recovery from acute toxic effects of any prior therapy, as deemed by the&#xD;
             Investigator or treating Sub-Investigator;&#xD;
&#xD;
          5. Adequate liver function as defined by the following laboratory values obtained within&#xD;
             28 days prior to administration of 64Cu-SARTATE: Aspartate aminotransferase (AST) and&#xD;
             alanine aminotransferase (ALT) &lt; 3.0 x upper limit of normal (ULN);&#xD;
&#xD;
          6. Adequate renal function;&#xD;
&#xD;
          7. Adequate laboratory parameters: Absolute neutrophil count &gt; 1.0 x 109/L; Platelet&#xD;
             count &gt; 50 x 109/L; Serum bilirubin &lt;1.5 x ULN;&#xD;
&#xD;
          8. Karnofsky or Lansky performance status ≥50;&#xD;
&#xD;
          9. All participants must have a hematopoietic stem cell product available (minimum CD34+&#xD;
             cell dose is ≥2 x 106 cells/kg);&#xD;
&#xD;
         10. Sexually active participants of reproductive potential must practice an effective&#xD;
             method of birth control while participating on this study, to avoid possible damage to&#xD;
             the fetus. Abstinence is considered acceptable;&#xD;
&#xD;
         11. 64Cu-SARTATE uptake on the 4 hour scan (SUVmax) of any lesion equal to or higher than&#xD;
             that of the liver in order to move on to the therapy phase of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants with disease of any major organ system that would compromise their&#xD;
             ability to tolerate therapy, as deemed by the Investigator or treating&#xD;
             Sub-Investigator;&#xD;
&#xD;
          2. Any other active malignancy, or a history of prior malignancy within the past 3 years;&#xD;
&#xD;
          3. History of cardiac failure as evidenced by: dyspnea at rest, exercise intolerance,&#xD;
             oxygen requirement, clinically significant cardiac dysfunction;&#xD;
&#xD;
          4. Planned administration of chemotherapy, anti-cancer cytokine therapy, immunotherapy,&#xD;
             radiotherapy or other investigational agents within 2 weeks prior to the&#xD;
             administration of 64Cu-SARTATE and 4 weeks prior to the administration of&#xD;
             67Cu-SARTATE;&#xD;
&#xD;
          5. Administration of therapeutic dose of 131I-MIBG within 8 weeks prior to the&#xD;
             administration of 64Cu-SARTATE;&#xD;
&#xD;
          6. EBRT to both kidneys or a single functioning kidney within 12 months prior to the&#xD;
             administration of 64Cu-SARTATE;&#xD;
&#xD;
          7. Administration of any investigational agents within 28 days prior to administration of&#xD;
             64Cu-SARTATE;&#xD;
&#xD;
          8. Treatment with long acting somatostatin analogues (administered within 28 days prior&#xD;
             to the administration of 64Cu-SARTATE), or short acting somatostatin analogues&#xD;
             (administered within 24 hours prior to the administration of 64Cu-SARTATE);&#xD;
&#xD;
          9. Known sensitivity or allergy to somatostatin analogues;&#xD;
&#xD;
         10. Previous PRRT;&#xD;
&#xD;
         11. Female participants who are pregnant or lactating;&#xD;
&#xD;
         12. Participants who are on hemodialysis;&#xD;
&#xD;
         13. QTc interval ≥ 0.45 seconds as measured by Screening ECG;&#xD;
&#xD;
         14. Participants with uncontrolled infection(s);&#xD;
&#xD;
         15. Any medical condition which the Investigator feels may interfere with the procedures&#xD;
             or evaluations of the study;&#xD;
&#xD;
         16. Participants 12 month and younger will be excluded from cohorts where the planned&#xD;
             single or cumulative administered activity is modelled to deliver a radiation dose to&#xD;
             the marrow that exceeds 2 Gy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clarity Pharmaceuticals</last_name>
    <phone>+61 (0) 2 9209 4037</phone>
    <email>clinicaltrials@claritypharmaceuticals.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Neeta Pandit-Taskar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Centre</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brian Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacquline Kraveka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Centre</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tanya Watt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kenneth DeSantes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 14, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Copper</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

